Medigene AG (0QGJ.L)
| Previous close | 1.4450 |
| Open | 0.0000 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 0.0000 - 0.0000 |
| 52-week range | |
| Volume | |
| Avg. volume | 128 |
| Market cap | 340,115 |
| Beta (5Y monthly) | 0.91 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Medigene's Global Research & Collaboration Agreement with BioNTech to Extend Beyond Initially Announced Term
Planegg/Martinsried, May 21, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of differentiated T cell immunotherapies for solid tumors and BioNTech SE (Nasdaq: BNTX, “BioNTech”) have announced that their collaboration to advance T cell receptor (TCR) immunotherapies against cancer will extend beyond the initial three-year term outlined at the signing of the agreement in February 2022. This ext
- GlobeNewswire
Medigene Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS
Planegg/Martinsried, May 15, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today presents the company’s proprietary T cell receptor (TCR) discovery process to obtain optimal affinity 3S (sensitive, specific and safe) TCRs at the 21th Association for Cancer Immunotherapy (CIMT) Annual Meeting in Mainz from May 15 - 17, 2024. Data presented also show
- Globe Newswire
Medigene AG Extends Cash Runway into July 2025 After Successful Oversubscribed Capital Raise
Cash runway extended into July 2025 from previously April 2025Capital raise strengthens Medigene’s financial positionLead program, MDG1015, on track for IND filing in 3Q 2024 and CTA filing in 4Q 2024Use of proceeds from recent capital raise further advances plans for first patient enrollment in MDG1015 Phase 1 dose escalation trial by end of 2024, subject to additional financing Planegg/Martinsried, May 14, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-onco
